Loading...
Market
By how much will Evotec's stock price increase due to the new collaboration by the end of 2024?
2
Resolution / Starting Odds
Increase by 0-5% • 25%
Increase by 5-10% • 25%
Increase by 10-15% • 25%
Increase by more than 15% • 25%
Stock market data from reputable financial platforms
Story
Evotec and Bristol Myers Squibb Expand Proteomics Partnership with $50 Million Upfront
Oct 23, 2024, 06:02 AM
Evotec SE and Bristol Myers Squibb have announced an expansion of their proteomics partnership, which will now include a new molecular glue-based collaboration. This collaboration begins with a $50 million upfront payment from Bristol Myers Squibb to Evotec. The partnership aims to build a molecular glue-based pipeline, leveraging the success of previous deals between the two companies. The new collaboration focuses on non-protac degraders.
View original story
Similar markets
Outperforms DAX by more than 10% • 25%
Outperforms DAX by up to 10% • 25%
Performs similar to DAX • 25%
Underperforms DAX • 25%
Successful acquisition at €11 per share • 25%
Acquisition at a different price • 25%
Acquisition fails • 25%
Acquisition postponed • 25%
Takeover completed • 25%
Takeover offer made but not completed • 25%
No takeover offer made • 25%
Triton sells its stake • 25%
Decrease by more than 20% • 25%
Decrease by less than 20% • 25%
Increase by less than 20% • 25%
Increase by more than 20% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Positive • 33%
Neutral • 33%
Negative • 34%
Roche • 25%
Novartis • 25%
Sanofi • 25%
No counteroffer • 25%